Pharmaceutical Landscape in the GCC: Key Insights and Statistics (2026)

Medicines are getting costly, chronic diseases are on the rise, and all pharmaceutical markets are racing to secure their drug supply so they can expand quickly; however, the GCC (Gulf Council Cooperation) pharmaceutical market is experiencing solid expansion, driven by growing healthcare demands, an increasing burden of chronic diseases, regulatory reforms, and ambitious initiatives to boost local manufacturing. The sector is on a sustainable pathway, supported by government investments in healthcare diversification.

All six GCC countries are undergoing a transformation that will reshape healthcare across the Middle East. But what is driving this transformation? If you have also wondered about it, stay tuned as we unfold stats, trends, and facts that you absolutely cannot afford to miss.

Pharma Market Overview

The pharmaceutical industry across the Gulf Cooperation Council is entering one of its strongest phases. Here’s what is happening:

Market Size and Growth:

• The GCC pharmaceutical market reached USD 23.7 billion in 2024 and is projected to grow to USD 49 billion by 2033, nearly doubling in less than a decade. Source
• Generics are booming across the region; the generics market is forecast to reach USD 15.9 billion by 2033, as governments opt for lower-cost alternatives. Source
• Digital transformation is accelerating the E-pharmacy market, which is projected to grow at an 11% CAGR, while pharmacy-management tech is expected to expand at nearly a 14% CAGR through 2035. Source | Source
• R&D momentum is rising, with many drugs currently under clinical trials across GCC markets.
• Biosimilars are surging, due to global patent cliffs and regional cost pressures. It is expected to be at a remarkable 15–20% CAGR, with oncology and immunology emerging as the leading therapeutic areas. Source

Key Regional Trends

1. Local Manufacturing

For global change, governments want to rely less on imported medication and produce more within their borders, so the supply chain never breaks, and people don’t have to wait for medication.

From Saudi Arabia’s Vision 2030 to the UAE’s industrial expansion programs, and even smaller markets like Oman, every country is introducing incentives to boost local drug production.

2. Generics & Biosimilars

For years, brands have dominated the market; however, with healthcare costs increasing, generics are now in demand.

People are even more open to Biosimilars, as they are the fastest-growing category, currently at 15–20% CAGR, particularly in oncology and immunology, where treatments can be quite expensive.

3. Digital Transformation

These days, more people order medicines online or get e-prescriptions. These pharmacy tools are becoming everyday realities because they aren’t about convenience; it’s about giving patients faster, safer, and more transparent access to the medicines they need.

4. Chronic Diseases Burden

The Gulf deals with some of the world’s highest rates of diabetes, obesity, and cardiovascular diseases.  People need chronic medications daily, sometimes for life, which makes the market more stable and predictable.

5. Clinical Trials & R&D growth

Hospitals, universities, and ministries are stepping up, creating research environments that didn’t exist before. The GCC has set its sights as a clinical research hub, and government bodies are collaborating to attract global trials.

6. Regulatory Harmonization

GCC regulators are progressing, from quick approval pathways to clearer biosimilar guidelines. Faster approvals mean new treatments reach patients sooner, and it’s changing perceptions of the Gulf as a bureaucratic market.

GCC Pharma by Country: Facts, Stats & Insights:

The GCC is growing, and each country has its own story, challenges, and pharma priorities.

1. Saudi Arabia: The Undisputed Regional Leader:

Saudi Arabia sits at the center of the pharma sector and holds over 50% of the GCC pharma market. With some of the biggest healthcare changes and localization targets, the Kingdom is on its way to reshape how medicines are produced and consumed across the Gulf.

Key Numbers
Market size (2024)	USD 10.5 – 12 billion
GCC Market share	50 – 55%
Projected size by 2030–2033	USD 18 – 21 billion
Expected CAGR	6 – 7%
Branded drug dominance	70 – 80%
Import dependency	70–80% (though it is now declining with new factories)

Source | Source

Saudi Arabia’s Pharma Market:

• Over 183,000 medical devices have received a marketing authorization license in Saudi Arabia. Source
• As of June 2024, SFDA had approved 19 drugs with pediatric orphan indications, covering about 50 pediatric orphan disease indications. Source
• Saudi Arabia heavily depends on drug imports, about 70%, but aims to locally manufacture around 40% of its pharmaceutical market by 2030. Source
• About 18% of approved pediatric orphan indications are for genetic diseases. Source
• The National Biotechnology Strategy aims to contribute SAR 130 billion to non-oil GDP by 2040 and create 11,000 jobs by 2030, with this number growing to 55,000 by 2040. Source
• SFDA has authorized 253 orphan drugs total, compared with 753 in the U.S. and 435 in the EU. Source
• SFDA registered 66 therapeutic biologic products, comprising 109 different formulations/strengths. Source
• The biosimilar market in Saudi Arabia was estimated at USD 2.8 billion in 2024 and is projected to grow to USD 4.9 billion by 2032. Source
• The biosimilar market in Saudi Arabia doubled in 2024, boosted by 38 SFDA drug approvals and strong healthcare funding. Source
• Saudi Arabia’s top-selling biologics market, valued at USD 6.8 billion in 2022, is set to nearly double to USD 14 billion by 2030, growing at about 9.4% annually. Source
• In October 2023, SFDA was recognized by the World Health Organization (WHO) as having reached Maturity Level 4 (ML4) for medicines and vaccines regulation. Source
• In 2023, SFDA conducted 84 inspections of medical device manufacturers (local + overseas). Source
• As of 2024, there are about 150 licensed medical device factories in Saudi. Source
• Since 2019, SFDA has run a proactive “Drug Safety Monitoring Program,” intending to detect safety issues early and take regulatory action. Source
• The acquisition of an Authorized Representative license reportedly takes about 1–2 weeks and must precede device registration/import procedures.
• SFDA issued 375 drug recall announcements. Source

2. United Arab Emirates: The Innovation & Logistics Hub

The UAE has emerged as the region’s innovation capital, blending biotech, digital health, advanced logistics, and a strong regulatory environment. It’s smaller than Saudi Arabia, but it adapts new technologies faster, which attracts foreign investment.

Key Numbers
Market size (2024)	USD 4.2 – 4.67 billion
Projected size by 2030	USD 8 billion
Expected CAGR	7.3 – 7.6%
Branded drug dominance	70 – 80%
Import dependency	About 80%

Source | Source

UAE’s Pharma Market:

• There are 6,176 generic medicines available in the UAE’s pharmaceutical market. Source
• Between 2010 and 2018, UAE authorities approved 187 new medicines containing novel active substances. Source
• According to a 2023 industry insights summary, there are 23 manufacturing centers in the UAE pharma sector. Source
• There are 464 pharmaceutical companies in the UAE as of 2025, which is a 5.20% increase from 2023. Source
• UAE manufacturers produce over 2,500 locally made medicines, which are projected to be worth $4.7 billion by 2025. Source
• By 2021, the number of pharmaceutical manufacturing units had grown to 23 (up from just 4 in 2010). Source
• Abu Dhabi’s AED 10B investment aims to double manufacturing to AED 172B, boost non-oil exports 148% to AED 178.8B, and create 13,600 jobs by 2031. Source
• By 2030, patented drugs are expected to make up 77% of the UAE prescription drug market. Source
• In 2024, the UAE captured 0.3% of the global pharmaceutical market revenue. Source

3. Kuwait: Big Spending, Huge Dependence on Imports

Kuwait is one of the highest per-capita spenders on pharmaceuticals in the region. Despite its smaller population, the demand for specialty care, new cancer centers, and chronic medications continues to spread.

Key Numbers
Market size (2024)	USD 6.52 billion
Projected size by 2030	USD 9.09 billion
Expected CAGR	5 – 6%
Import dependency	80%

Source

What’s Driving Kuwait’s Pharma Market

• There are about 121 pharmaceutical companies listed in Kuwait (as of May 2025), which is an 8.04% increase from 2023. Source
• In 2025, Kuwait’s Ministry of Health approved at least 751 new drugs, products, and supplements across several batches, including 392 in October alone, chosen from 1,580 reviewed applications. Source
• In March 2025, Kuwait’s Ministry of Health approved prices for 146 medicines and supplements in private pharmacies. Source
• In 2025, Kuwait adjusted prices for 69 new medicines in private pharmacies, lowering costs for most high-demand drugs in line with Vision 2035. Source
• The CDMO market in Kuwait is forecast to grow to USD 8 million by 2033. Source
• It is estimated that 80% of drugs consumed in the country are imported, reflecting high import dependence. Source
• The only local manufacturer (Kuwait Saudi Pharmaceutical Industries Company) produces around 120 generic products for local supply and the MENA regions. Source

4. Qatar: Small Population, Big Per-Capita Spending

Qatar is a small but high-value pharma market with one of the highest per-capita pharma expenditures in the GCC. Despite a relatively high level of import dependence, it is investing in long-term pharmaceutical capabilities.

Key Numbers
Market size (2024)	USD 1.1 billion
Projected size by 2030	USD 1.3 billion
Expected CAGR	4.2%
Import dependency	97%

Source

What’s Driving Qatar’s Pharma Market

• Qatar has 3 local pharmaceutical factories operating. Source
• Historically (as of that 2016 listing), there were about 4,599 registered pharmaceutical products in Qatar. Source
• Locally manufactured drugs account for 10% of the total number of products registered with the health authorities. Source
• According to a 2025 public forecast report, the national pharmaceutical market (drugs) is projected to generate USD 479.8 million in 2025. Source
• The specialized medications/oncology drugs segment is forecast at USD 86.57 million. Source
• As of 2017, there were about 305 community pharmacies in Qatar. Source
• Branded or patented medicines account for nearly 69.5% of all drug sales in Qatar. Source
• Around 75% of drugs distributed in Qatar are prescription-only, with OTC and other medicines making up the remaining quarter. Source

5. Oman: A Market Growing Steadily with Big Future Potential

Oman has a modest-sized market but has one of the strongest healthcare expansions in the GCC. Its Infrastructure projects, an aging population, and new insurance reforms are all fueling demand.

Key Numbers
Market size (2024)	USD 0.3
Projected size by 2030	USD 0.5 – 0.6 billion
Expected CAGR	5 – 7%
Import dependency	95%

Source

What’s Driving Oman’s Pharma Market

• The total value of health sector activity reached RO 1.1224 billion, marking a 31% increase since 2018. Source
• Oman’s population is 5.17 million (used in regulatory / pharmacovigilance reporting). Source
• Exports of health-sector-related goods increased by 31%, reaching RO 37.86 million. Source
• As of 2022, imports remain a major part of supply: health sector imports were valued at RO 287 million, an increase of 21% since 2018. Source
• Locally manufactured pharmaceuticals in Oman accounted for just 4.6% of total medicine purchases; 95.4% were imported. Source
• The 722 pharmaceutical companies collectively have 3,909 registered products. Source
• National production capacity has shown encouraging growth, from a mere 1.8% in 2021 to 4.7% in 2022. Source

6. Bahrain: The Smallest Market but Extremely Cost-Sensitive

Bahrain has the smallest pharmaceutical market in the GCC, but has one of the highest levels of cost regulation and generic promotion.

Key Numbers
Market size (2024)	USD 0.6 – 0.7 billion
Expected CAGR	6 – 7%
Import dependency	91%

Source | Source

What’s Driving Bahrain’s Pharma Market

• According to the National Health Regulatory Authority (NHRA), there are 4,211 registered medicines in Bahrain. Source
• In 2023, NHRA licensed 51 new pharmacies, bringing the total number of licensed pharmacies to 434, an increase of 6% since 2022. Source
• The NHRA reviewed 743 applications for new medicine registration, 509 renewal applications, 1,012 medicine variation applications, and 386 product classification cases. Source
• The total number of healthcare professionals with active licenses under NHRA reached 22,060. Source
• For pharmaceutical product importers (medicines/medicinal products), there are 20 active importers in 2024–2025. Source
• Across the healthcare sector, 12,135 CPD activities have received approval for professional development. Source
• The Medical Devices Control section reviewed 11,404 applications for new medical devices and approved 10,142. Source

GCC Challenges & Risks

While the pathway is stable, there are several risks and challenges to watch out for:

• Import Dependency: Despite tremendous efforts to produce locally, many GCC countries still rely heavily on imported drugs, making them vulnerable to global supply chain risks.
• Regulatory Barriers: Even with reforms, regulatory complexity differs across countries; harmonization is limited.
• R&D Funding: Building a robust local R&D ecosystem is capital-intensive; not all GCC countries may sustain it equally.
• Cost Pressures: As generics gain market share, branded drug companies may face pricing pressure.
• Talent & Manufacturing Capacity: Scaling manufacturing (especially biologics) requires specialized talent, infrastructure, and investment.

GCC Outlook and Opportunities

Given the current situation, here’s what could happen in the near to mid-term, and where the opportunities lie:

• Market Expansion: The Gulf pharma market could approach USD 49 billion by 2033.
• Local Production Gains: Countries that invest in manufacturing (especially biosimilars) can reduce import dependence and improve margins.
• Digital Pharma: E-pharmacy, digital prescribing, and pharmacy management systems will likely become more mainstream, offering both business and patient-care opportunities.
• R&D Hubs: GCC can become a clinical-trial and biotech hub, especially for biosimilars, if regulatory alignment and investment continue.
• Personalized & Specialty Medicine: As compounding pharmacies grow, specialized and personalized therapies (oncology, pediatrics) will become more accessible.
• Public-Private Partnerships: Governments could partner with global pharma to localize production or co-develop biosimilars, thereby boosting local capacity.

Conclusion:

The pharmaceutical industry in the GCC is at a critical moment, driven by demographic shifts, chronic disease, and major health investments; the market is on a fast growth path. The Gulf is transforming from an oil hub to a knowledge and health center.